Attention deficit / hyperactivity disorder (ADHD) is defined by DSM-IV criteria, which shows inattention, hyperactivity and impulsivity. ADHD is one of the most common child psychiatric disorders, more likely to be seen in males, and the prevalence is estimated approximately 5% in the UK (NICE ADHD guideline). ADHD is often prominent in early childhood and persist through adolescence to adulthood.
Conditions
Interventions
Product Name: Eye Q
Pharmaceutical Form: Capsule, soft
Pharmaceutical form of the placebo: Capsule, soft
Route of administration of the placebo: Oral use
Sponsors
King's College London (IOP)
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Male adolescents aged 12-17 with 1)Both Conners’ Parents ADHD Rating Global Score and Conners' Teachers Rating Global Score are above 65 2)Meet ADHD criteria using a semi-structured interview (CHIPS; Weller, 2000) based on DSM-IV criteria. All subjects will score higher than 70 on the prorated IQ as measured by The Kaufman Brief Intelligence Test (K-BIT) (Chin, 2001). Only right handed males will be tested EEG Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1) Subjects who took omega-3 supplement within 6 months 2) A personal history of diabetes or other metabolic disorder influencing fatty acid metabolism 3) Subjects whose IQ is less than 70 4) Subjects who are not living in a family home or residential school 5) Subjects who are not in school during the intervention 6) Subjects who are non-English speakers 7) Serious or chronic disease 8) Low blood coagulation function (e.g. haemophilia, hepatic dysfunction, low-vitamin K) 9) Under these Medication: alpha tocopherol, selected anticoagulants (aspirin, warfarin, heparin), cyclosporine, clopidogrel, etretinate and topical steroids, cholesterol-lowering medications (atorvastatin, lovastatin, and simvastatin), non-steroidal anti-inflammatory drugs (NSAIDs), dalteparin, dipyrdamole, enoxaparin, ticlopedine, other nutritional supplements. 10) Known allergy for fish product derivatives, Vitamin E derivatives, gelatine, olive oil 11) Pancreatic insufficiency 12) abnormal blood data: Triglyceride For the EEG studies only, subjects with left handed, neurological problems or substance abuse will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: ADHD symptoms are often carried through to the adolescent period and long-term intervention is often needed. Patients and their parents often choose alternative treatments for ADHD. Omega-3 fatty acids supplementation is one popular alternative treatment, and relatively safe, but the effectiveness has not been assessed enough . This study aims to evaluate whether EFA supplementation improves ADHD symptoms in ADHD male adolescents. ;Secondary Objective: In addition, these secondary questions are to be assessed: Does a fatty acids deficiency symptoms score correlate with blood phospholipid levels of essential fatty acids and the symptoms of hyperactivity disorder? Is there any relationship between electroencephalography, ADHD symptoms and fatty acids status? ;Primary end point(s): •Omega-3 fatty acids supplementation improves Conners’ teacher rating scale ADHD global score in ADHD male adolescents. •Omega-3 fatty acids supplementation improves Conners’ parent rating scale ADHD global score in ADHD male adolescents. | — |
Countries
United Kingdom
Outcome results
None listed